Brought to you by 
Genentech collaborates with start-up RQx on compounds in infectious diseases
16 Apr 2013
Executive Summary
Start-up RQx Pharmaceuticals Inc. and Roche’s Genentech Inc. have agreed to discover and develop compounds against an undisclosed target in infectious diseases, focusing on antibiotic resistance.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech collaborates with start-up RQx on compounds in infectious diseases
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice